Monitor Nasdaq compliance through November 9, 2026; watch for any further dilutive financings or ELOC draws that could pressure the stock price. The massive share registration relative to the tiny float (5,442% of outstanding) creates extreme overhang risk.
Executive Summary
Glucotrack, Inc. filed an S-1 registration statement to register up to 43,447,017 shares of common stock for resale by selling stockholders, representing approximately 5,442% of the outstanding shares as of September 14, 2026 (798,390 shares). The filing covers shares issuable upon conversion of bridge notes, exercise of warrants, and under an ELOC purchase agreement with White Lion Capital LLC for up to $50 million. The company has a going concern qualification, a history of losses, and is at risk of Nasdaq delisting.
Key Facts
- Registration of up to 43,447,017 shares for resale, representing ~5,442% of outstanding common stock (798,390 shares as of Sept 14, 2026)
- Company has a going concern qualification with accumulated deficit of ~$156.2 million as of March 31, 2026 and cash of ~$3.9 million
- Nasdaq delisting risk: received Staff Determination on May 11, 2026 for non-compliance with Bid Price Rule; regained compliance with Equity Rule on Aug 14, 2026 but must maintain bid price ≥$1.00 through Nov 9, 2026
- Bridge Financing: issued senior secured convertible notes for ~$7.95 million gross proceeds with 22% OID, 8% interest, 9-month maturity
- ELOC Purchase Agreement with White Lion Capital: up to $50 million of common stock over 3 years; stockholder approval obtained Sept 11, 2026 to remove 19.99% exchange cap
- September PIPE Financing: issued $11.6 million principal amount of notes for $4.5 million cash and exchange of $4.5 million in bridge notes, with 22% OID
- Company is a smaller reporting company with no revenue from operations; pre-revenue clinical-stage biopharma and medical device development
- Independent auditor's report includes going concern emphasis of matter for year ended Dec 31, 2025
Financial Impact
Potential dilution of up to 5,442% of outstanding shares; $50 million ELOC facility with 25% of proceeds to repay bridge investors and 50% to Glucotrack Technologies subsidiary
Risk Factors
- Extreme dilution risk: registered shares represent 5,442% of outstanding common stock
- Nasdaq delisting risk: must maintain bid price ≥$1.00 through Nov 9, 2026; new MVLS rule could trigger delisting
- Going concern risk: accumulated deficit of $156.2M, only $3.9M cash as of March 31, 2026
- Pre-revenue with no approved products; both subsidiaries (CBGM and LT-100) are in clinical/preclinical stages
- Variable rate convertible instruments with reset provisions could cause further dilution
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-043195 |
| Exhibit: ex107.htm | 0001493152-26-043195 |
| Exhibit: ex5-1.htm | 0001493152-26-043195 |
| Exhibit: ex23-1.htm | 0001493152-26-043195 |
| Exhibit: ex23-3.htm | 0001493152-26-043195 |
| Exhibit: ex23-2.htm | 0001493152-26-043195 |
| Document: 0001493152-26-043195-index-headers.html | 0001493152-26-043195 |
| Document: 0001493152-26-043195-index.html | 0001493152-26-043195 |
| Document: 0001493152-26-043195.txt | 0001493152-26-043195 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.4032 | awaiting T+60 | — | $1.61 (−299.31%) |
Oct 19, 2026 7d ago | 8-K | $0.6511 | awaiting T+60 | — | $1.61 (+147.27%) |
Oct 13, 2026 13d ago | S-1/A | $0.8873 | awaiting T+60 | — | $1.61 (−81.45%) |
Oct 13, 2026 13d ago | 425 | $0.8873 | awaiting T+60 | — | $1.61 (+81.45%) |
Sep 28, 2026 28d ago | 8-K | $1.74 | awaiting T+60 | — | $1.61 (−7.47%) |
Sep 24, 2026 4w ago | 424B5 | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 24, 2026 4w ago | 8-K | $1.82 | awaiting T+60 | — | $1.61 (+11.54%) |
Sep 23, 2026 4w ago | 425 | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 23, 2026 4w ago | 8-K | $2.03 | awaiting T+60 | — | $1.61 (−20.69%) |
Sep 18, 2026 5w ago | 8-K | $2.30 | awaiting T+60 | — | $1.61 (−30.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers